Valuation Corbus Pharmaceuticals Holdings, Inc.
Stocks
CRBP
US21833P3010
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
10:13:47 2026-08-24 EDT
|
5-day change | 1st Jan Change | ||
| 9.915 USD | -4.48% |
|
-6.58% | +20.39% |
| 08-13 | Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating | MT |
| 08-07 | Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating | MT |
Company Valuation: Corbus Pharmaceuticals Holdings, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 77.1 | 13.84 | 26.72 | 143.7 | 150.8 | 200.8 | - | - |
| Change | - | -82.05% | 93.01% | 437.89% | 4.94% | 33.11% | - | - |
| Enterprise Value (EV) | 77.1 | 13.84 | 26.72 | 143.7 | 150.8 | 200.8 | 200.8 | 200.8 |
| Change | - | -82.05% | 93.01% | 437.89% | 4.94% | 33.11% | 0% | 0% |
| P/E | -1.66x | -0.33x | -0.59x | -3.21x | -1.38x | -1.89x | -1.81x | -1.79x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.04x | -0.37x | 0x | -0x | 0.27x | -0.37x | -1.96x |
| Capitalization / Revenue | 87.4x | - | - | - | - | 181x | 83.7x | 79.9x |
| EV / Revenue | 0x | - | - | - | - | 181x | 83.7x | 79.9x |
| EV / EBITDA | - | - | - | -0x | - | -1.76x | -1.71x | -1.12x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -1.69x | -1.49x | -1.15x |
| EV / FCF | -0x | -0x | - | -0x | -0x | -1.66x | -1.6x | -1.34x |
| FCF Yield | -62.6% | -271% | - | -29.1% | -42.8% | -60.3% | -62.5% | -74.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -11.1 | -10.15 | -10.31 | -3.68 | -5.9 | -5.48 | -5.749 | -5.801 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.8817 | - | - | - | - | 1.111 | 2.4 | 2.511 |
| EBITDA 1 | - | - | - | -48.13 | - | -114 | -117.3 | -179.2 |
| EBIT 1 | -55.99 | -39.84 | -45.08 | -48.72 | -85.31 | -118.4 | -134.7 | -174.3 |
| Net income 1 | -45.64 | -42.35 | -44.6 | -40.21 | -78.54 | -116.3 | -135.2 | -171.2 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 18.47 | 3.32 | 6.04 | 11.80 | 8.14 | 10.38 | 10.38 | 10.38 |
| Nbr of stocks (in thousands) | 4,174 | 4,176 | 4,424 | 12,179 | 18,529 | 19,341 | - | - |
| Announcement Date | 3/8/22 | 3/7/23 | 3/12/24 | 3/11/25 | 3/9/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.89x | - | - | - | 201M | |
| 21.45x | 7.54x | 15.37x | 1.38% | 72.12B | |
| 37.53x | 9.72x | 29.82x | 0.04% | 65.85B | |
| -18.08x | 7.59x | -9.85x | -.--% | 29.28B | |
| -79.5x | 14.86x | -71.64x | -.--% | 27.47B | |
| 33.76x | 6.66x | 17.64x | -.--% | 26.7B | |
| 27.2x | 5.1x | 17.12x | -.--% | 20.06B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.22B | |
| 2460.33x | 41.28x | -5047.29x | -.--% | 16.4B | |
| 16.73x | 4.96x | 11.58x | -.--% | 13.4B | |
| Average | 255.04x | 13.03x | -555.29x | 0.19% | 28.97B | |
| Weighted average by Cap. | 152.90x | 11.04x | -277.31x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CRBP Stock
- Valuation Corbus Pharmaceuticals Holdings, Inc.
Select your edition
All financial news and data tailored to specific country editions
